BioCentury
ARTICLE | Company News

Progenics regains cancer vaccine rights

May 15, 2001 7:00 AM UTC

PGNX and Bristol-Myers Squibb (BMY) jointly decided to end their 1997 collaborative development agreement for PGNX's GMK and MGV cancer vaccines. Under the termination, PGNX received $15.5 million and regained all rights to the products. ...